Current clinical trials
Breast Cancer Clinical Trials
Neo N - Recruiting
A phase II trial evaluating the efficacy of nivolumab or nivolumab plus relatlimab with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers.
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377957&isReview=true
NATALEE
A trial to evaluate the efficacy and safety of Ribociclib with Endocrine therapy as adjuvant treatment in patients with HR=/HER2-ve early breast cancer
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=18322&isClinicalTrial=True
VIKTORIA 1 - Recruiting
A Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
https://clinicaltrials.gov/ct2/show/NCT05501886
LAAVA2 - Recruiting
Laser therapy for vulvovaginal symptoms in breast cancer patients (LAAVA 2)
CAPItello-292 - Recruiting
A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
https://clinicaltrials.gov/study/NCT04862663?term=capitello-292&rank=1
Optima - Recruiting
Optimal Personalised Treatments of Early Breast Cancer Using Multi-Parameter Analysis
https://www.isrctn.com/ISRCTN42400492
Spear - Recruiting
A phase 2, open-label, single-arm monotherapy trial of Sulfasazine inpatients with PancrEatic AdenocaRcinoma
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382642
Gastrointestinal Cancer Clinical Trials
Challenge
A phase III study of the impact of a physical activity program on disease –free survival in patients with high risk stage II or stage III colon cancer: a randomised controlled trial
http://clinicaltrials.gov/show/NCT00819208
OXTOX - Recruiting
Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study
https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12619000566134
Germ Cell Cancer Clinical Trials
P3BEP - Recruiting
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor risk metastatic germ cell tumours
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364125
Climate - Recruiting
Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour, following orchidectomy.
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=383439&isReview=true
Haematological Cancer Clinical Trials
Canova
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (CANOVA)
https://clinicaltrials.gov/ct2/show/NCT03539744
FrontMIND
A Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in high intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
https://clinicaltrials.gov/study/NCT04824092?term=frontmind&rank=1
Melanoma Clinical Trials
HBI-8000-313
This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with new, progressive brain metastasis will be stratified by PD-L1 expression and LDH level.
https://clinicaltrials.gov/ct2/show/NCT04674683
Prostate Cancer Clinical Trials
AnzADAPT - Recruiting
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)
https://www.clinicaltrials.gov/study/NCT05393791
Mic-1 - Recruiting
Phase II Study to Investigate the Ability of Macrophage Inhibitory Cytokine-1 (MIC-1)
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335301
Enzamet
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365575
Enzarad
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365611
Embark
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With HighRisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
HENGRUI
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT04691804
Capitello 280 - Recruiting
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
https://clinicaltrials.gov/ct2/show/NCT05348577
DASL-HiCap
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer
https://clinicaltrials.gov/study/NCT04136353?term=dasl&rank=1
Arastep - Recruiting
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
https://clinicaltrials.gov/study/NCT05794906?term=darolutamide%20arastep&rank=1
Wombat - Recruiting
Working Out M0 Bipolar Androgen Therapy (WOMBAT) - ANZUP 2201
https://uat.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387659
Solid Tumours Clinical Trials
Oric 114-01 - Recruiting
An Open-Label, Phase 1/1b, Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration